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Abstract: Copper is an essential trace element required by all living organisms. Excess amounts of copper, however, results in cellular 
damage. Disruptions to normal copper homeostasis are hallmarks of three genetic disorders: Menkes disease, occipital horn syndrome, 
and Wilson’s disease.  
Menkes disease and occipital horn syndrome are characterized by copper deficiency. Typical features of Menkes disease result from low 
copper-dependent enzyme activity. Standard treatment involves parenteral administration of copper-histidine. If treatment is initiated be-
fore 2 months of age, neurodegeneration can be prevented, while delayed treatment is utterly ineffective. Thus, neonatal mass screening 
should be implemented. Meanwhile, connective tissue disorders cannot be improved by copper-histidine treatment. Combination therapy 
with copper-histidine injections and oral administration of disulfiram is being investigated. Occipital horn syndrome characterized by 
connective tissue abnormalities is the mildest form of Menkes disease. Treatment has not been conducted for this syndrome. 
Wilson’s disease is characterized by copper toxicity that typically affects the hepatic and nervous systems severely. Various other symp-
toms are observed as well, yet its early diagnosis is sometimes difficult. Chelating agents and zinc are effective treatments, but are ineffi-
cient in most patients with fulminant hepatic failure. In addition, some patients with neurological Wilson’s disease worsen or show poor 
response to chelating agents. Since early treatment is critical, a screening system for Wilson’s disease should be implemented in infants. 
Patients with Wilson’s disease may be at risk of developing hepatocellular carcinoma. Understanding the link between Wilson’s disease 
and hepatocellular carcinoma will be beneficial for disease treatment and prevention. 
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I. INTRODUCTION 
  Copper is an essential element required by cuproenzymes, in-
cluding cytochrome C oxidase, lysyl oxidase, dopamine ß-
hydroxylase, superoxide dismutase, tyrosinase, ascorbic acid oxi-
dase, and ceruloplasmin. When in excess, copper’s oxidative poten-
tial can induce free radical production and result in cellular damage. 
In particular, adequate copper nutrition is critical during pregnancy 
and lactation for normal infant development [1]. Thus, tight regula-
tion of copper homeostasis, maintained by mechanisms involving 
uptake, transport, storage, and excretion of copper, is required [2]. 
Disruptions to normal copper homeostasis are fundamental features 
of Menkes (kinky hair) disease (MD) [3, 4], occipital horn syn-
drome (OHS) [5], and Wilson’s disease (WD)
 [6]. Each disease is 
caused by the absence of or defect in two copper-transporting AT-
Pases encoded by the ATP7A gene (responsible for MD and OHS) 
[7-11] and ATP7B gene (responsible for WD) [12-15].  
  ATP7A and ATP7B proteins have similar functions in cells; 
however, the pathology and clinical manifestations associated with 
MD and OHS are completely different compared to WD. MD and 
OHS, for example, are characterized by copper deficiency, and WD 
by toxicity due to excess copper. This difference relates to the par-
ticular cell type expressing ATP7A and ATP7B. ATP7A is ex-
pressed in almost all cell types except hepatocytes, whereas ATP7B 
is mainly expressed in hepatocytes. Diagnostic approaches are 
mostly established for these diseases, and treatments for MD and 
WD have been proposed. However, unsolved problems relating to 
disease diagnosis and management still exist [16-18]. Here we re-
view genetic disorders of copper transport, and highlight clinical 
problems relating to their diagnosis and treatment.  
II. COPPER HOMEOSTASIS 
 Figure  1 highlights the general mechanism of copper metabo-
lism in humans [17,19]. The average daily copper intake is 2-5 mg 
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in healthy adults. Copper is predominantly absorbed in the duode-
num and small intestine where it is transported into the liver via the 
portal vein. Most of the absorbed copper is excreted in bile, but a 
small fraction is excreted in urine. Several parameters affect the 
absorption rate of dietary copper, including age, sex, food type, 
amount of dietary copper, and oral contraceptives. These parame-
ters could cause the adsorption rate to vary between 12 to 71% [20]. 
A study using 
65Cu isotope showed that a daily copper intake of 0.8 
mg is sufficient to maintain homeostasis in adults [21]. Figs 2a and 
3a show copper metabolism in normal cells. The high-affinity cop-
per transporter (CTR1) is localized to the plasma membrane and 
mediates copper uptake. Copper uptake occurs in the intestinal 
brush border; however, the specific mechanism by which dietary 
Cu(II) is reduced to a Cu(I) ion remains unknown [20,22]. Addi-
tional copper transporters, CTR2 and divalent metal transporter 1 
(DMT1), may contribute to copper uptake in the intestine, although 
to a lesser extent compared to CTR1 [20,22].  
  Cytosolic copper is delivered to Cu/Zn superoxide dismutase in 
the cytosol, Golgi apparatus, and mitochondria via the copper 
chaperones, CCS2, ATOX1 (HAH1), and COX 17, respectively 
[17,22]. In addition, cytosolic metallothionein maintains copper 
homeostasis in cells [23]. 
  The liver is the central organ that maintains copper homeosta-
sis. In hepatocytes, copper is excreted via two major pathways: bile 
and blood. In the excretion pathway leading to the blood, copper is 
delivered to the trans-Golgi network by ATOX1, and transported 
across by ATP7B located on the trans-Golgi membrane. Copper is 
transferred as a Cu(I) ion from ATOX1 to the fourth metal binding 
domain of ATP7B [24]. Once in the trans-Golgi network, copper is 
incorporated into apo-ceruloplasmin, reduced to holo-ceruloplas-
min, and then excreted as ceruloplasmin into the blood. Approxi-
mately 90% of serum copper is bound to ceruloplasmin, while the 
remaining 10% is bound to albumin or carried as amino acid-bound 
copper (non-ceruloplasmin-bound copper), which is likely the form 
transported into various tissues. Similarly, the pathway mediating 
copper excretion from the liver to bile also requires ATP7B. 
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MURR1, is also involved in copper excretion to the bile. Although 
most intracellular copper-binding proteins, such as ATP7A and 
ATP7B, bind copper as Cu(I), COMMD1 has been reported to bind 
copper as Cu(II) [25], and may be an important component of the 
intracellular system for utilizing, detecting, or detoxifying Cu(II) 
[26]. Bedlington Terriers, for example, have a COMMD1 defect 
which causes copper toxicosis in the liver due to insufficient biliary 
copper excretion [27]. Serum copper and ceruloplasmin levels in 
Bedlington Terriers are not low, indicating that ATP7B function is 
intact. Tao et al showed that the carboxyl terminus of COMMD1 
dimerizes (and oligomerizes) as efficiently as its full-length coun-
terpart, and attributed a major protein-protein interaction role to this 
acidic residue-rich region [28]. Indeed, ATP7B and COMMD1 may 
cooperate to facilitate biliary copper excretion [25-29], and may 
thus explain why biliary copper excretion is affected in WD. 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Copper metabolism in humans.  
ATP7B, copper-transporting P-type ATPase. Solid and dashed arrows show main and minor pathways in copper transport, respectively. Values in parentheses 
show amounts in adult males. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Copper metabolism in normal cells versus those affected by Menkes disease. 
CTR1, copper transporter 1; ATP7A, copper-transporting P-type ATPase ; , copper. Left, copper metabolism in normal cells. Right, copper metabolism in 
cells affected by Menkes disease. In cells affected by Menkes disease, copper cannot be transported from the cytosol to the Golgi apparatus. As a result, copper 
accumulates in the cytosol and cannot be excreted from the cells. Copper deficiency in the Golgi apparatus results in a decrease in the activities of secretory 
copper enzymes such as lysyl oxidase (LOX) and dopamine -hydroxidase (DBH). 
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  Genetic disorders involving copper metabolism are character-
ized by either copper deficiency or accumulation, which manifest in 
the form of MD, OHS, and WD (Table 1). Recently, missense mu-
tations in ATP7A, resulting in normal protein levels but defects in 
copper trafficking, have been identified and reported to cause X-
linked distal hereditary motor neuropathy without overt signs of 
systemic copper deficiency [30].  
III. GENE, STRUCTURE, AND FUNCTION OF ATP7A AND 
ATP7B 
 The  ATP7A gene maps to chromosome Xq13.3 and encodes a 
protein that is 1,500 amino acids long with a molecular weight of 
165 kDa [7-9]. ATP7A protein is expressed in almost all tissues 
except the liver. In an animal model of MD, ATP7A is expressed in 
astrocytes and cerebrovascular endothelial cells comprising the 
blood-brain barrier, as well as in neurons and choroid plexus cells, 
indicating that ATP7A plays a role in intracellular copper transport 
in these cell types [31,32]. In contrast, the ATP7B gene maps to 
chromosome 13q14.3 and encodes a protein that is 1,411 amino 
acids long [12-15]. The overall sequence homology between 
ATP7A and ATP7B is 56%, with greater homology observed in the 
phosphate domain (78%), transduction and phosphorylation do-
mains (89%), and ATP-binding domain (79%). ATP7B is predomi-
nantly expressed in the liver, kidney, and placenta, and poorly ex-
pressed in the heart, brain, lung, muscle, pancreas, and intestine. 
The function of ATP7B in non-liver tissues remains unclear.  
  ATP7A and ATP7B contain six amino-terminal metal binding 
domains, a phosphorylation and phosphatase domain, and eight 
transmembrane domains (Fig. 4). Each protein contains six repeat-
ing motifs, GMXCXXC, that bind copper stoichiometrically as 
copper(I) ion at 5-6 nmol of copper/nmol of protein. This suggests 
that each motif binds one copper atom. ATP7A and ATP7B are 
predominately localized in the trans-Golgi network and transport 
copper from the cytosol into the Golgi apparatus. When copper 
levels rise inside cells, ATP7A and ATP7B traffic towards the 
plasma membrane to excrete excess copper [33]. Functional assays 
involving yeast complementation [34,35] and insect cells [36]
 have 
been reported, however, these assays are too complicated to stan-
dardize and use in a clinical test. Establishing a functional assay 
that can be used clinically to test for ATP7A and ATP7B activity 
will be beneficial not only for diagnosis of these disorders, but also 
to study genotype-phenotype correlations. 
IV. MENKES DISEASE (MD) AND OCCIPITAL HORN 
SYNDROME (OHS) 
4.1. Genetics 
 
  Genetic disorders associated with mutations in the ATP7A gene 
are clinically divided into three categories: classical MD (referred 
to as MD in this review), mild MD, and OHS. MD and OHS are 
both X-linked recessive disorders which typically occur in male 
patients. In Japan, the incidence of MD is estimated to be 1/140,000 
live male births [37]. Patients diagnosed with MD have a large 
variety of mutations in the ATP7A gene [17,38-40]. About 357 
different mutations, including insertions and deletions (22%), non-
sense (18%), missense (17%), partial deletions (17%), and splice-
site mutations (16%) have been described [40]. Furthermore, ge-
Table 1.  Characteristics of Inherited Copper Transport Disorders in Humans 
Characteristics   Menkes Disease  Occipital Horn Syndrome  Wilson’s Disease 
Inheritance  X-linked recessive  Autosomal recessive 
Prevalence  1/140,000 male births  Rare  1/30,000-1/35,000 
Responsible gene  ATP7A ATP7B 
Gene location  Xq13.3  13q14.3 
Gene product  Copper-transporting P-type ATPase (ATP7A)  Copper-transporting P-type ATPase (ATP7B) 
Expression   Almost all tissues except liver  Liver, kidney, placenta, lung, brain, heart, muscle, 
pancreas, and intestine. 
Mutations  No common mutations  Splice-site mutations, missense 
mutations 
R778L and H1069Q substitutions are common in 
Asian and European patients, respectively. 
Pathogenesis  Defect of intestinal Cu absorption; 
reduced activities of Cu-dependent 
enzymes 
Partial defect of intestinal Cu ab-
sorption; reduced activities of Cu-
dependent enzymes 
Copper toxicosis; defects of biliary Cu excretion 
and Cu incorporation into ceruloplasmin in the 
liver; copper accumulates in various tissues 
Clinical features  Severe neurological degeneration, 
abnormal hair, hypothermia, and con-
nective tissue disorders 
Connective tissue disorders, gait 
abnormalities, muscle hypotonia 
Liver diseases, neurological diseases and psychiat-
ric manifestations, Kayser-Fleischer rings, hema-
turia, arthritis, cardiomyopathy, and pancreatitis 
Laboratory features  Decreased serum Cu and ceruloplas-
min, and increased Cu concentrations 
in cultured fibroblasts 
Slightly decreased serum Cu and 
ceruloplasmin, increased Cu con-
centrations in cultured fibroblasts, 
and exostosis on occipital bones 
Decreased serum Cu and ceruloplasmin, increased 
urinary Cu excretion, and increased liver Cu 
concentration 
Treatment Cu-histidine  injections    Chelating agents (e.g., penicillamine, trientine), 
zinc and liver transplantation 
Animal models  Macular and brindled mice   Blotchy mouse  LongEvans Cinnamon (LEC) rat 
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netic analysis indicates that about 75% of patient’s mothers are 
carriers, while the remaining 25% are not. This observation sug-
gests that new mutations in ATP7A gene have been acquired in MD 
patients [41]. Cases of MD in females have been reported, but are 
rare. In a recent study, Sirleto et al. described 8 females who re-
portedly had MD, and showed that 5 of them carried X-linked 
chromosomal abnormalities [42]. 
  OHS is the mildest and a rare form of MD, although the preva-
lence has not been reported. Mild MD has also been reported, and 
exhibits intermediate phenotypes between classical MD and OHS 
[40]. Most ATP7A gene mutations occurring in OHS and mild MD 
are splice-site or missense mutations [10,40]. Thus, residual 
ATP7A activity can exist [38-40].  
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Copper metabolism in normal and abnormal (affected by Wilson’s disease) hepatocytes. CTR1, copper transporter 1; ATP7B, copper-transporting P-
type ATPase ; Cp, ceruloplasmin; : copper. 
Left, copper metabolism in normal hepatocytes. Right, copper metabolism in hepatocyte of patient with Wilson’s disease. In hepatocytes affected by Wilson’s 
disease, copper cannot be transported from the cytosol to the Golgi apparatus due to a defect in ATP7B, so copper accumulates in the cytosol. Copper defi-
ciency in the Golgi apparatus results in reduced secretion of copper into the blood as ceruloplasmin, during which biliary excretion of copper is disturbed. 
Accumulated copper in the hepatocyte is released into the blood as non-ceruloplasmin-bound copper, although the mechanism is unclear. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). Domain organization and catalytic cycle of human copper-ATPases (ATP7A and ATP7B). 
A: membrane topology and domain organization of Cu-ATPase; MBDs, metal-binding domains; A-domain, the actuator domain; P-domain, phosphorylation 
domain; N-domain, nucleotide-binding domain. Modified from Lutsenko et al. Physiol Rev. 2007, 87: 1011. Used with permission. 
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  Mottled mutant mice are proposed animal models of MD and 
OHS, and mutations in the Atp7a gene have been identified in these 
mutant mice. These brindled and macular mice show phenotypic 
features similar to classical MD, whereas blotchy mice have promi-
nent connective tissue abnormalities and resemble OHS. These 
mice have been used in many biochemical and treatment studies 
[43].  
4.2. Pathology  
  ATP7A is localized in the trans-Golgi membrane and transports 
copper from the cytosol into the Golgi apparatus in almost all cell 
types, excluding hepatocytes. In MD, copper accumulates in the 
cytosol of affected cells and cannot be excreted (Fig. 2b). Electron 
microscopy reveals that copper accumulates in cytoplasmic apices 
of absorptive epithelial and vascular endothelial cells, and in secre-
tory granules of Paneth cells located in the intestine of macular 
mice [44]. Intestinal accumulation of copper results in absorption 
failure, which leads to copper deficiency in the body and reduced 
cuproenzyme activity. Copper also accumulates in cells comprising 
the blood-brain barrier and choroid plexus, indicating that copper is 
not transported from blood vessels to neurons [31,32,45,46]. The 
characteristic features of MD can be explained by a decrease in 
cuproenzyme activity (Table 2). These enzymes include cyto-
chrome C oxidase (localized in the mitochondria), tyrosinase, and 
Cu/Zn superoxide dismutase (localized in the cytosol). Decreased 
enzyme activity of these enzymes that are localized in the mito-
chondria and the cytosol in the affected cells, excluding the brain, 
can be improved by parenteral copper administration.  
  At present, the accepted therapy involves subcutaneous copper-
histidine injections. Unfortunately, cuproenzyme activity in neurons 
cannot be improved by treatment since copper accumulates in the 
mature blood-brain barrier and fails to be transported into neurons 
[45-47]. Neuropathological abnormalities are observed in MD, 
especially in the cerebral cortex and cerebellum. Brain atrophy, 
diffusely narrowed gyri, and widened sulci are among the abnor-
malities observed. Other abnormalities include loss of Purkinje cells 
and neuronal loss of cerebellar molecular and internal granule 
cell layers [48]. Neurodegeneration in MD results mainly from 
decreased cytochrome C oxidase activity in neurons. In addition, 
subdural hemorrhage occurs secondary to abnormalities in brain 
arteries due to decreased activities of lysyl oxidase, which causes 
neurological damage.  
  Connective tissue abnormalities are caused by decreased lysyl 
oxidase activity. Lysyl oxidase combines with copper in the Golgi 
Table 2.  Cuproenzymes and Symptoms Due to Decreased Activity (Symptoms of Menkes Disease) 
Enzyme (Localization in Cells or Charac-
teristics) 
Function Symptoms 
Cytochrome C oxidase  
(mitochondria) 
Electron transport in mitochondrial respiratory 
chain, energy production 
Brain damage, hypothermia, muscle hypotonia  
Lysyl oxidase 
(secretory enzyme) 
Crosslinking of collagen and elastin   Arterial abnormalities, subdural hemorrhage, bladder 
diverticula, skin and joint laxity, osteoporosis, bone 
fracture, hernias  
Dopamine ß-hydroxylase (secretory enzyme)   Norepinephrin production from dopamine  Hypotension, hypothermia, diarrhea [121] * 
Tyrosinase 
(cytosol) 
Melanin formation  Hypopigmentation 
Sulfhydryl oxidase 
(cytosol) 
Keratin cross-linking  Abnormal hair 
Cu/Zn superoxide dismutase 
(cytosol) 
Oxidant defense: superoxide radical detoxica-
tion 
CNS degeneration [121] 
Peptidyl -amidating monooxygenase 
(secretory enzyme [122]) 
Neuropeptide bioactivation   Brain damage 
Ceruloplasmin 
(secretory enzyme) 
Ferroxidase, Cu transport  Anemia 
Hephaestin** 
(membrane bound enzyme [123]) 
Ferroxidase in enterocytes, involved in iron 
absorption 
Anemia 
Angiogenin** 
(secretory enzyme [122]) 
Induction of blood vessel formation, antimi-
crobial host defense [125] 
Arterial abnormalities, enteric infections [126] ** 
Amine oxidases**  Oxidation of primary amines, cancer growth 
inhibition and progression [127] 
Carcinogenesis [127] ** 
Blood clotting factors V, VIII**  Blood coagulation system [128]  Blood clotting [128] ** 
* Diarrhea is often observed in patients with MD, but the relation with dopamine ß-hydroxylase is unclear.  
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apparatus and is secreted from the cells. Accordingly, parenteral 
administration of copper-histidine cannot improve enzyme activi-
ties because the administered copper is not transported into the 
Golgi apparatus due to ATP7A defects. In fact, serum and urine 
levels of bone metabolic markers are poorly improved by copper-
histidine therapy in patients with MD [49]. Neurochemical patterns 
in the serum and cerebrospinal fluid of patients with MD resembled 
that of patients with congenital deficiencies of dopamine -
hydroxylase, suggesting that this enzyme activity is reduced in 
patients with MD [50]. Dopamine ß-hydroxylase is also a secretory 
enzyme, and thus its enzyme activity could not be increased by a 
copper-histidine injection. Another characteristic feature of MD is 
severe muscular hypotonia. Although the pathology of muscular 
hypotonia remains unknown, reduced activity of cytochrome C 
oxidase in muscles may be involved [51]. In the kidneys of macular 
mice, copper accumulates in the cytosol of proximal tubular cells, 
but not in the distal tubules or glomeruli [44] .  
  In contrast, OHS is characterized by connective tissue disorders 
caused by decreased lysyl oxidase activity.  
4.3. Clinical Features  
  Characteristic clinical features of MD and OHS are summarized 
in Tables 1 and 2, and are shown in Figs. 5-9. Developmental delay, 
seizures, and marked muscular hypotonia become prominent after 
two months of age when copper deficiency is advanced. Diagnosis 
is difficult prior to two months of age because clinical abnormali-
ties are subtle or sometimes absent in affected newborns [52]. Neu-
rodegeneration and connective tissue abnormalities do not improve 
and progress when copper-histidine therapy is initiated at 2 months 
of age or older. As the disease progresses, patients become bedrid-
den and are unable to smile or speak. Although most patients die by 
the age of three, a few survive beyond 20 years of age [40,52]. 
  Epilepsy, including infantile spasms, myoclonus, multifocal 
seizures, and tonic spasms, are observed in over 90% of patients 
with MD who have been treated after 2 months of age [53,54]. 
Magnetic resonance imaging (MRI) reveals brain atrophy and de-
layed myelination or demyelination, and subdural hemorrhage is 
often observed (Fig. 7). Magnetic resonance angiography (MRA) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (5). Depigmented, lusterless, and kinky hair in a 3-month-old patient 
with Menkes disease. Hair abnormalities were improved by copper-histidine 
injections. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (6). A 2 year-old patient with Menkes disease treated with copper-
histidine injections since the age of 8 months. Despite treatment, he suffers 
from severe muscle hypotonia and cannot hold up his head.  
 
 
 
 
 
 
 
 
 
 
 
Fig. (7). Brain CT images of a patient with Menkes disease at 2, 8, and 11 
months of age. The image was taken at the age of 2 months because of a 
head injury. This was prior to diagnosis of MD as no neurological symp-
toms were observed at that time. The patient was diagnosed with MD at the 
age of 8 months, with brain atrophy progressing despite copper-histidine 
treatment. Subdural hemorrhage was observed in the patient at 11 months of 
age. 
 
reveals tortuosity of intracranial and cervical blood vessels [16]. 
1H-magnetic resonance spectroscopy (MRS) shows a lactate peak 
and decreased N-acetylaspartate and creatinine/phosphocreatine 
levels [55]. Lesions of hypointensity on T1-weighted images and 
hyperintensity on T2-weighted images are transiently observed in 
temporal lobes, and appear similar to stroke-like lesions observed in 
mitochondrial myopathy, encephalopathy, lactate acidosis, and 
stroke-like episodes (MELAS). This suggests that the lesions ob-
served in MD may be due to ischemic events [56].  
  Hair abnormalities, including kinky, tangled, depigmented, 
friable, and sparse hair, are characteristic features of MD and often 
diagnostic (Fig. 5). Bladder diverticula, osteoporosis, skin and joint 
laxity, and arterial abnormalities are connective tissue changes 
caused by decreased lysyl oxidase activity. Patients with MD have 
intractable and chronic diarrhea that results in severe malnutrition; 
however, the etiology is unclear. Urinary infection is common and 
most likely due to bladder diverticula. Although severe copper tox-
icity is not typically observed, urinary ß2-microglobulin levels are 
elevated in patients, suggesting that toxicity does occur in renal 
proximal tubules [57]. 
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Fig. (8). Connective tissue abnormalities in the patient with Menkes disease 
shown in Fig 7. Images on the left and right were taken just before treatment 
and at 2 years of age (also during the treatment period), respectively. Blad-
der diverticula formation (upper) and osteoporosis (lower) progressed de-
spite treatment. Arrows show bone fractures. 
 
Fig. (9).  a) Skin laxity in a 18 year-old patient with occipital horn syn-
drome. b) MRA showing tortuosity of cerebral arteries (arrow). c-d) Occipi-
tal horns are shown in a skull X-ray (c) and MRI T1 WI (d) (arrows). 
 
  Clinical features of OHS include mild muscle hypotonia and 
connective tissue abnormalities, including exostosis on occipital 
bones, bladder diverticula, and skin and joint laxity (Fig. 9). How-
ever, neurological abnormalities are milder compared to classical 
MD, and include ataxia, dysarthria, mild hypotonia, and mild men-
tal retardation [40]. Clinical and biochemical heterogeneity has 
been reported in siblings with the same missense mutation, suggest-
ing that clinical features depend not only on genetic, but also non-
genetic mechanisms [58]. 
 
 
4.4. Diagnosis 
  Diagnosis is not difficult once clinical features, such as intrac-
table seizures, connective tissue abnormalities, subdural hemor-
rhage, and hair abnormalities, appear. However, treatment with 
copper-histidine once neurological symptoms appear is too late to 
prevent neurological disorders. Thus, early diagnosis and treatment 
is critical for the neurological prognosis of MD. Hair abnormalities 
and episodes of temporary hypothermia may be clues for an early 
diagnosis, as these are typically observed prior to the appearance of 
neurological symptoms. However, diagnosing MD before the age of 
2 months is difficult because hair abnormalities and temporary hy-
pothermia are also often observed in normal, premature babies. In 
contrast to serum copper and ceruloplasmin levels, which are sig-
nificantly lower, copper concentrations in cultured fibroblasts from 
patients are significantly higher, and can help to provide a definitive 
diagnosis. Carrier and prenatal diagnosis can be made by mutation 
analysis once a mutation has been identified in the patient’s family 
[41].  
  Male patients with muscle hypotonia and skin laxity should be 
suspected of OHS. Such patients can be screened by a simple brain 
X-ray to identify exostoses on occipital bones. Because serum cop-
per and ceruloplasmin can range from normal to low levels in pa-
tients with OHS, diagnosis of OHS cannot be made solely on the 
basis of serum levels of copper and ceruloplasmin. Like MD, cop-
per concentrations are high in cultured fibroblasts from patients, 
and thus are useful for diagnosing OHS [39,40]. A DNA-based 
diagnosis is also available for OHS [38,40]. 
4.5. Mass Screening 
  Copper-histidine therapy prior to neurological manifestations 
would be more efficient if patients with MD could be identified 
through neonatal mass screening. Because serum copper and ceru-
loplasmin are physiologically low in normal infants, measuring 
such parameters in patients with MD would not be a useful neonatal 
screening method. We recently developed a screening method to 
test for MD based on the ratio of homovanillic acid to vanillylman-
delic acid present in urine [59]. However, although a neonatal mass 
screening using blood samples has been performed worldwide to 
test for other genetic diseases, the same system using urine samples 
has yet to be implemented. Our method would be easily applicable 
if mass screening was performed using urine samples. Kaler et al. 
reported that the ratios of dopamine to norepinephrine and dihy-
droxphenylacetic acid to dihydroxyphenylglycol in the plasma can 
help with early diagnosis of MD, and that these neurochemicals can 
be detected by high-throughput tandem mass spectrometry, a tech-
nique which is currently used in neonatal mass screening of other 
inherited diseases [60]. This test would need to be adapted for mass 
screening to apply it as a broad strategy with public health applica-
tions. 
4.6. Treatments  
  The current treatment strategy for MD is parenteral copper ad-
ministration. Among the available copper components, copper-
histidine has been reported to be the most effective [61]. Copper-
histidine injection improves hair abnormalities (Fig. 5), copper 
concentrations in liver, and serum levels of copper and ceruloplas-
min. However, neurodegeneration progresses if copper-histidine 
therapy is initiated after the onset of neurological symptoms. One 
possible explanation is that the administered copper accumulates at 
the blood-brain barrier and is not transported to neurons [46]. If 
treatment is initiated neonatally and while the blood-brain barrier is 
still immature, neurodegeneration can be prevented in some patients 
[61-64]. A recent study conducted on 24 patients with MD showed 
that only 12.5% of patients treated with copper during early infancy 
(6 weeks of age) retained clinical seizures. Moreover, five patients  
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with known mutations resulting in partial ATP7A function had 
neither clinical seizures nor electroencephalographic abnormalities 
[65]. These findings suggest that differences in treatment response 
would also depend on residual ATP7A activity. Symptoms relating 
to connective tissue disorders are scarcely improved by copper-
histidine treatment. This is explained by the fact that the adminis-
tered copper cannot be transported from the cytosol into the Golgi 
apparatus where it is incorporated into lysyl oxidase. Patients with 
MD who are diagnosed and treated early show phenotypic features 
of OHS. Unfortunately, no treatment trials have been reported in 
patients with OHS. 
  An effective treatment for neurological and connective tissue 
disorders has not yet been established. If the delivery of copper into 
the trans-Golgi apparatus of affected cells could be achieved, then 
copper treatment would probably normalize the activity of lysyl 
oxidase and improve connective tissue disorders associated with 
MD and OHS. Likewise, if copper could be delivered to the Golgi 
apparatus within cells comprising the blood-brain barrier, copper 
would reach neurons and be incorporated into cuproenzymes in-
cluding cytochrome C oxidase in the neurons. We previously re-
ported that combination therapy with copper and diethyldithiocar-
bamate (DEDTC, Fig. 10), a lypophilic chelator, improves copper 
concentration, cytochrome C oxidase activity, and catecholamine 
metabolism in the brains of macular mice (Fig. 11) [66]. Takeda et 
al reported a 3-year-old patient treated with copper-histidine and 
oral disulfiram (DEDTC dimmer) for a period of 2 years [67]. Se-
rum copper and ceruloplasmin levels increased and were higher 
than those when patients were administered copper-histidine alone. 
In addition, we observed a smile from the patient administered the 
combination therapy. The hydrophobicity of DEDTC seems to sup-
port passage of copper chelated with this compound through the 
membrane. To establish the utility of this therapy, further studies 
focusing on survival, biochemical parameters, and clinical outcome 
in both animal models and patients with MD are necessary.  
 
 
 
 
 
 
 
 
 
Fig. (10). Chemical reaction of chelation by sodium N,N-
diethyldithiocarbamate. 
 
 
 
 
 
 
 
 
 
 
Fig. (11). Copper concentrations (Cu) and cytochrome C oxidase (CCO) 
activity in the cerebrum of macular mice. MA, macular mice treated with 
copper and DEDTC; MB, macular mice treated with copper only; MC, 
macular mice without treatment. (*p<0.05; ** p<0.01. 
 
V. WILSON’S DISEASE (WD) 
5.1. Genetics  
  The global prevalence of WD is approximately 1/30,000 new-
borns, although this varies across populations [68]. This autosomal 
recessive disorder is caused by mutations in the ATP7B gene, and 
over 480 mutations have been reported (http//www.medgen.med. 
ualberta.ca/database). The R778L substitution is the most common 
mutation occurring in Asian patients, while the H1069Q mutation is 
mostly seen in European patients [17,69,70]. A correlation between 
genotype and phenotype has not been found in patients with WD, 
although several mutations correlate well with an early onset of the 
disease [71,72]. WD manifestations may be influenced by gene 
variants of baculoviral IAP repeat-containing protein 4/X-linked 
inhibitor of apoptosis protein (BIRC4/XIAP), which is anti-
apoptotic and likely acts as a regulator of copper-induced cell death 
[73]. Gupta et al recently reported that a 9-year-old and 6-month-
old patient with high neurological predominance and mild hepatic 
symptoms not only had heterozygous mutations in ATP7B, but also 
had mutations in COMMD1 [74]. The authors, however, concluded 
from a genetic analysis of 108 patients that COMMD1 variants do 
not contribute to the phenotypic heterogeneity observed in WD. 
  Two animal models have been reported for WD. Long-Evans 
Cinnamon (LEC) rats harbor a deletion in the ATP7B gene, accu-
mulate large amounts of copper in the liver, and develop chronic 
hepatitis, which eventually leads to hepatocellular carcinoma 
[75,76]. Toxic milk mice have a mutation in the transmembrane 
domain of atp7b, and show decreased levels of ceruloplasmin with 
accumulation of copper in the liver, which eventually leads to cir-
rhosis [77]. 
5.2. Pathology 
  Copper cannot be transported from the cytosol into the Golgi 
apparatus, where copper is incorporated into apo-ceruloplasmin in 
hepatocytes of patients with WD. Accordingly, secretion of copper 
as holo-ceruloplasmin into the blood is affected. Excretion of cop-
per into bile is also affected (Fig 3b), resulting in copper accumula-
tion in the liver. During the early stage of the disease, copper is 
diffusely distributed as metallothionein-copper in the hepatocytic 
cytosol. With disease progression, copper accumulates in the 
lysosomes. This excess copper induces free radical production, 
which causes cellular damage via oxidative stress. Furthermore, 
serum levels of ceruloplasmin decrease, at which point ceruloplas-
min-bound copper decreases in the serum. Excess copper in the 
liver is released into the plasma as non-ceruloplasmin-bound cop-
per, i.e., copper bound to albumin or amino acids, although the 
release mechanism is unclear [78]. The increase in serum non-
ceruloplasmin-bound copper results in elevated urinary copper ex-
cretion and copper deposition in various tissues, including the brain, 
kidney, cornea, muscle, bone, and joint [17]. 
  Iron as well as copper reportedly accumulates in the liver of 
patients with WD [79]. Due to the oxidase activity in ceruloplas-
min, which converts ferrous iron to ferric iron, decreased ceru-
loplasmin levels in WD disrupt iron homeostasis [80]. Liver dam-
age in patients with WD may be caused, in part, by iron accumula-
tion, which is also toxic to the liver [79].  
5.3. Clinical Features  
  Prominent clinical features of WD include hepatic and neuro-
logical/psychiatric symptoms. Hepatic symptoms range from acute 
and chronic hepatitis to cirrhosis and fulminant hepatic failure. 
Although serum levels of transaminases are high in infants with 
WD, hepatic disorders usually occur after 8 years of age. Neuro-
logical symptoms appear after 12 years of age and are characterized 
by extrapyramidal effects, which include dysarthria, dystonia, 
tremor, choreoathetosis, and ataxia [81]. Cognitive impairment and 
depression are also common in patients with WD. Seizures occur 
with a prevalence of 4-8.3% and are sometimes associated with de-
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coppering therapy [82]. The types of seizures can vary, and include 
generalized tonic-clonic (grand mal), simple partial, complex par-
tial, and partial seizures with secondary and generalized periodic 
myoclonus [82]. Early diagnosis and initiation of treatment is cru-
cial, especially for patients with neurological symptoms. Copper 
levels in the cerebrospinal fluid are elevated in patients with neuro-
logical symptoms, but decrease to normal ranges following treat-
ment. Thus, copper levels could be a useful marker for monitoring 
patients with neurological symptoms [83]. “Face of giant panda 
sign,” tectal plate hyperintensity, central pontine myelinosis (CPM-
like), and concurrent changes in basal ganglia, thalamus, and brain-
stem are observed in MRIs from patients with neurological WD 
[84,85]. High signal T1 images, similar to those in portal-systemic 
encephalopathy, are also observed [85]. In addition, loss of cerebral 
white matter has rarely been reported (Fig 12). 
31P- and 
1H-MRS 
indicate that reduced breakdown and/or increased synthesis of 
membrane phospholipids, as well as increased neuronal damage in 
basal ganglia, occur in patients with neurological WD [86]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (12). Loss of left frontal cerebral white matter in a neurological patient 
with Wilson’s disease who suffered right hemiplegia.  
 
  Initial symptoms, such as microscopic hematuria, proteinuria, 
hemolytic anemia, epistaxis, arthritis, cardiomyopathy, dysrhyth-
mias, hyperpigmentation (similar to Addison’s disease), cataracts, 
amenorrhea, and hypersalivation, vary and make early diagnosis 
difficult [17,87,88]. Kayser-Fleischer rings are also common in 
neurological WD, which reflect copper deposition in the brain (Fig 
13). However, about 40% and 20% of patients with hepatic and 
neurological symptoms, respectively, show no Kayser-Fleischer 
rings [88-90]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (13). Kayser-Fleischer rings. 
5.4. Diagnosis 
  Guidelines for the diagnosis of WD were approved in 2008 by 
the American Association for the Study of Liver Diseases 
(AASLD) [89]. Diagnosis is based on low serum copper and ceru-
loplasmin levels (<20 mg/dL; immunoassay), high copper concen-
trations in the liver (>250 g/g dry weight), high copper excretion 
in the urine (>100 g/day), and by conducting a penicillamine chal-
lenge test (urinary copper excretion >1,600 or 1,057 g/day) 
[89.91]. In some patients with WD, however, serum copper and 
ceruloplasmin levels are not low [88,89]. In fact, serum copper 
levels are often high in patients with WD suffering from acute liver 
failure due to the release of accumulated copper in hepatocytes. 
Furthermore, other hepatic diseases, including autoimmune hepati-
tis and intrahepatic cholestasis, may affect serum copper measure-
ments and make diagnosis difficult. DNA-based diagnosis (e.g., 
high-resolution melting analysis or HRM) has also been reported 
[92]. However, approximately 17% of patients diagnosed with WD 
based on clinical symptoms and biochemical data have no muta-
tions in the coding regions of ATP7B [69]. Scoring systems for the 
diagnosis of WD have been proposed in order to account for the 
deficiencies of any one test [93]. Although a diagnosis can be made 
in the vast majority of cases, a small number of patients cannot be 
diagnosed with the tests described above [94]. Once a patient is 
diagnosed with WD, all first- and second-degree relatives should 
also be screened for the disease. Treatment should be offered to 
presymptomatic patients, although diagnosis in some cases can be 
challenging. 
5.5. Screening  
  Clinical manifestations of WD show considerable variation, 
making early diagnosis challenging. The median time interval be-
tween presentation of initial symptoms and diagnosis is 18 months 
(ranging from 1-72 months) for patients with neurological symp-
toms and 6 months (ranging from 2-108 months) for patients with 
hepatic symptoms [90]. Despite current strategies, the mean delay 
from presentation of initial symptoms to diagnosis is two years 
(ranging from 0.08-30 years) [95]. This is mainly due to the low 
awareness and index of suspicion by primary care physicians [95]. 
Awareness and diagnosis could be improved by implementing 
medical education strategies that target primary care physicians.
 
  Early diagnosis is possible through mass screening strategies, 
which also enable the detection of presymptomatic patients. Holo-
ceruloplasmin detections in newborn blood or in urine of 3-6 year-
old children have been proposed as potential mass screening strate-
gies [96-98]. To date, however, mass screening has not yet been 
implemented anywhere. The specificity and sensitivity of these 
methods require further investigation, as well as a cost-benefit 
analysis when applied at the population level. Ultimately, innova-
tive methods that allow mass screening for WD need to be devel-
oped.  
5.6. Therapy 
  The therapeutic aim for WD is to remove excess copper that 
accumulates in the body. When patients are diagnosed with WD, 
they should be promptly treated with chelating agents, including 
penicillamine and trientine, and/or zinc (Table 3) [89]. Chelating 
agents should be taken on an empty stomach because food prevents 
their absorption. These agents are usually recommended to be taken 
1 hour before or 2 hours after meals. The treatment choice depends 
on hepatic or neurological manifestations, severity of symptoms, 
pregnancy, and presymptomatic conditions [89,99]. In addition, 
patients should avoid food and water containing high concentra-
tions of copper. 
  Treatment should continue throughout the patient’s life, with 
routine monitoring of serum and urine copper, blood cell counts, 
coagulation parameters, and testing for liver and renal function 
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tients who receive the full treatment [100]. Urinary copper excre-
tion increases above 1000 g/day for a few months following peni-
cillamine or trientine treatment (initial treatment). These levels 
range between 200-500 g/day during maintenance therapy with a 
chelating agent [89].  
Penicillamine 
  While penicillamine is the most effective treatment for remov-
ing copper through urine excretion, it is associated with severe side 
effects [101]. These side effects include immunological conditions 
(e.g., lupus-like reactions, nephrotic syndrome, myasthenia gravis, 
and Goodpasture syndrome), skin defects (e.g., degenerative 
changes and elastosis perforans serpiginosa), and joint disorders 
(e.g., arthropathy). Given these side effects, trientine is now the 
preferred method of treatment [89,99].  
Trientine 
 Figure  14 shows the chemical structure of trientine. Trientine is 
known to remove copper from the blood compartment, and in-
creases urinary copper excretion. Zinc and iron are also excreted 
with trientine, although in lesser amounts [102]. Trientine shares 
some of penicillamine’s side effects, but appears to be significantly 
less toxic and as efficacious as penicillamine [103]. For this reason, 
trientine is the recommended chelator for treatment of patients with 
hepatic WD [99].  
Zinc 
  Zinc is a recommended treatment for presymptomatic patients 
and for maintenance therapy of WD [99]. Zinc treatment of patients 
with WD results in increased levels of non-toxic zinc-bound metal-
lothionein. The enterocyte metallothionein induced by zinc inhibits 
copper uptake from the intestinal tract, resulting in a negative cop-
per balance [104]. Zinc is also thought to protect against copper 
toxicity in the liver by promoting sequestration of free copper in a 
non-toxic, metallothionein-bound form [105]. Treatment adequacy 
is determined by measuring non-ceruloplasmin-bound copper levels 
in the serum (5-15 g/dL), 24-hour urinary copper excretion (<75 
g/day) [89], or by spot urinary copper excretion with less than 
0.075  g/mg creatinine [106]. Non-ceruloplasmin-bound copper 
levels in the serum can usually be calculated from serum copper 
and ceruloplasmin levels using the following equation: 
  non-ceruloplasmin-bound copper levels in the serum (g/dL) = 
serum copper level (g/dL) – 3 x serum ceruloplasmin level 
(mg/dL) 
  This is possible because approximately 3.15 g of copper is 
bound to one mg of ceruloplasmin.  
Tetrathiomolybdate (TTM) 
  TTM is an anti-copper drug with a unique mechanism of action 
developed for patients with neurological WD. It has 4 sulfur groups 
that allow it to form a tripartite and stable interaction with copper 
(Fig  14). If given with food, TTM forms a stable complex with 
copper, rendering it unavailable for absorption. When given without 
food, however, it is well absorbed and complexes with free serum 
copper. TTM treatment does not result in serum copper spikes typi-
cally observed with penicillamine and trientine [107]. This may 
explain why neurological worsening is rare with TTM treatment 
versus other chelating agents [108], although a patient receiving 
TTM treatment was reported to develop status epilepticus [109]. 
While TTM is now preferred over other chelating agents for treat-
ment of neurological WD, the FDA recently decided that further 
studies are required before it can be used in patients with neurologi-
cal WD (from HP of Pipex Parmaceuticals Comp). 
Patients with Neurological Symptoms 
  In patients with neurological symptoms, clinical worsening is 
observed during the first few weeks of treatment in approximately 
50% and 26% of patients treated with penicillamine and trientine, 
respectively. In addition, 25% of patients treated with penicillamine 
are at risk of permanent neurological damage and may not recover 
to baseline levels of function [110]. Neurological worsening during 
initiation of anti-copper therapy is attributed to spikes in levels of 
serum non-ceruloplasmin-bound copper which occur during mobi-
lization of large stores of copper in the liver [107]. Although neuro-
logical worsening is also observed in a few patients treated with 
zinc, which is slow-acting, zinc alone or combination therapy with 
zinc and trientine are now recommended in patients with neurologi-
cal WD [99,111,112]. Another problem is that neurological symp-
toms sometimes do not completely subside with treatment. Liver 
transplantation in some patients with neurological disorders was 
reported to resolve neurological symptoms associated with WD. 
However, detailed neurological evaluations in these patients were 
not carried out [113]. Because early treatment is critical in patients 
exhibiting neurological disorders, medical education efforts target-
ing primary care physicians should be implemented in order to 
improve early diagnosis [81]. 
 
 
Table 3. Pharmacological Therapy for Wilson’s Disease 
Drug  Mode of Action  Maintenance Dose  Side effects 
Trientine  Induction of urinarycopper excre-
tion by chelating action 
750-1,000 mg/day three times 
a day; children, 20-25 
mg/kg/day 
Gastritis, in rare cases aplastic anemia and sideroblastic 
anemia, neurological deterioration during initial phase of 
treatment (about 26% [130]) 
D-Penicillamine  Induction of urinary copper excre-
tion by chelating action 
750-1,000 mg/day three times 
a day; children: 20 mg/kg/day 
Fever, rash, proteinuria, lupus-like reation, aplastic ane-
mia, leukopenia, thrombocytopenia, nephrotic syndrome, 
degenerative change in skin, elastosis perforans serpin-
gosa, serous retinitis, hepatotoxicity, neurological deterio-
ration during initial phase of treatment (about 50% [110]) 
Zinc  Blockage of copper absorption by 
inducing metallothionein in entero-
cytes 
150 mg/day, three times a 
day; children: 50-75 mg/day  
Gastritis, biochemical pancreatitis, zinc accumulation, 
possible changes in immune function 
Tetrathiomolybdate  Detoxifying copper in plasma and 
blocking copper absorption by com-
plexation with copper 
20 mg, three times with meals 
and three times between 
meals [108] 
Anemia, neutropenia, hepatotoxicity, neurologic deteriora-
tion during initial treatment (about 4% [108]) Inherited Cu Disorders  Current Drug Metabolism, 2012, Vol. 13, No. 3    247 
Patients with Hepatic Symptoms 
 Patients  with  mild and moderate liver disorders are initially 
treated with chelating agents (trientine preferred over penicil-
lamine) [89,99]. Serum levels of aminotransferases and non-
ceruloplasmin-bound copper are normalized a few months after 
initial treatment, reaching adequate urinary copper excretion levels 
that range between 200-500 g/day. Once this occurs, maintenance 
therapy is initiated with zinc alone or with a lower dose of chelating 
agents (i.e., trientine). In patients with fulminant hepatitis or hemo-
lysis, liver transplantation is the most likely solution [114].  
  One major obstacle regarding long-term treatment of patients 
with WD is poor drug compliance. A recent report showed that 
25% of patients were not persistently taking their medication, re-
sulting in deterioration and occasionally fatal outcomes [115]. Ac-
cordingly, it is important for physicians to make an effort to pro-
mote compliance during therapy. 
  Hepatocellular carcinoma (HCC) has become an important 
issue for patients with WD as current treatments have improved life 
expectancy. In a previous study, we examined the characteristics of 
25 WD patients with HCC and compared them to non-WD patients 
with HCC in a cohort from the Liver Cancer Study group in Japan, 
1994-2003 (LCS-J) [17]. The average age at diagnosis of HCC in 
WD patients was considerably lower compared to non-WD patients. 
In addition, male to female ratios were high in WD patients. Taken 
together, these results show that patients with WD (mainly males) 
are in danger of developing HCC despite treatment. The mechanism 
that leads to carcinogenesis in WD remains unknown and is cur-
rently under investigation. LEC rats harboring a deletion in ATP7B 
develop HCC [76]. Tsubota et al reported that mRNA expression of 
tumorigenic proteins, Ras GTPase-activating-like protein 
(IQGAP1) and vimentin, was induced by persistent oxidative stress 
in the liver of LEC rats, making these proteins important clinical 
targets for HCC [116]. Production of oxygen and nitrogen reactive 
species, and unsaturated aldehydes that arise from copper overload 
in patients with WD has been reported to cause mutations in the 
p53 tumor suppressor gene [117]. These findings suggest that oxi-
dative stress is associated with HCC. Vitamin E may act as an anti-
oxidant adjunct for WD therapy [118]. The copper chelating agent, 
TTM, inhibits angiogenesis, fibrosis, and inflammation [119,120]. 
However, how these affect HCC development is unclear. Elucida-
tion of these mechanisms will help devise strategies aimed at pre-
venting HCC in patients with long-term WD. 
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